We studied the composition of circulating immune complexes precipitated in the presence of various concentrations of polyethylene glycol in patients with coronary heart disease (CHD) and high concentration of lipoprotein(a) — Lp(a). Precipitation of highly purified Lp(a) preparation with polyethylene glycol was evaluated. The contents of Lp(a), autoantibodies to Lp(a), IgG, and IgM in circulating immune complexes isolated from the sera of donors and CHD patients with normal and high levels of Lp(a) were measured. Circulating immune complexes containing Lp(a) were detected in the plasma of CHD patients with high Lp(a) concentrations. The presence of high concentrations of Lp(a), autoantibodies to Lp(a), and circulating immune complexes in CHD patients suggests that immunological factor contributes to high atherothrombogenicity of Lp(a).
Similar content being viewed by others
References
Afanas’eva OI, Adamova IYu, Benevolenskaya GF, Pokrovskii SN. Comparison of three methods of isolating lipoprotein (a) from human blood plasma. Bull. Exp. Biol. Med. 1992;113(3):345-348.
Afanas’eva OI, Adamova IYu, Benevolenskaya GF, Pokrovskii SN. Enzyme immunoassay of lipoprotein(a). Bull. Exp. Biol. Med. 1995;120(4):1030-1033.
Afanasieva OI, Klesareva EA, Levashov PA, Berestetskaya YuV, Ezhov MV, Artemieva NV, Pokrovsky SN. Autoantibodies against Lipoprotein(a) in patients with coronary heart disease. Kardiologiya. 2014;54(6):4-8. Russian.
Gurevich VS, Urazgildeeva SA, Buthashvili MI, Vasina LV. Evolution of the knowledge about pro- and antiatherogenic properties of lipoproteins. Ateroskleroz Dislipidemii. 2012;(4):54-63. Russian.
Moskalev AV, Tsugan VN, Chechetkin AV. Laboratory Methods for Immune Status Evaluation. Medical Laboratory Technologies. Karpishchenko AI, ed. Moscow, 2013. Vol. 2. P. 243-337. Russian.
Nemov VV, Popkova MI. Patent RF No. 2415430. Method for Detecting Circulating Immune Complexes. Bull. No. 9. Published March 27, 2011.
Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, Binder CJ, Hörkkö S, Krauss RM, Chapman MJ, Witztum JL, Tsimikas S. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 2008;49(10):2230-2239.
Jin Y, Manabe T. Analysis of PEG-fractionated high-molecularmass proteins in human plasma by non-denaturing micro 2-DE and MALDI-MS PMF. Electrophoresis 2009;30(20):3613-3621.
Laczik R, Szodoray P, Veres K, Szomják E, Csípo I, Sipka S Jr, Shoenfeld Y, Szekanecz Z, Soltész P. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus. 2011;20(7):730-735.
Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J. Atheroscler. Thromb. 2013;20(10):743-754.
Missala I, Kassner U, Steinhagen-Thiessen E. Systematic literature review of the a of lipoprotein(a) and autoimmune diseases and atherosclerosis. Int. J. Rheumatol. 2012;2012. ID 480784. doi: 10.1155/2012/480784.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010;31(23):2844-2853.
Oda M, Uchiyama S, Noda M, Nishi Y, Koga M, Mayanagi K, Robinson C.V, Fukui K, Kobayashi Y, Morikawa K, Azuma T. Effects of antibody affinity and antigen valence on molecular forms of immune complexes. Mol. Immunol. 2009;47(2-3):357-364.
Riches K, Porter KE. Lipoprotein(a): cellular effects and molecular mechanisms. Cholesterol. 2012;2012. ID 923289.
Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008;200(2):239-246.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 162, No. 8, pp. 195-201, August, 2016
Rights and permissions
About this article
Cite this article
Klesareva, E.A., Afanas’eva, O.I., Donskikh, V.V. et al. Characteristics of Lipoprotein(a)-Containing Circulating Immune Complexes as Markers of Coronary Heart Disease. Bull Exp Biol Med 162, 231–236 (2016). https://doi.org/10.1007/s10517-016-3583-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-016-3583-z